Wolfe Research analyst Andrew Rosivach upgrades SBA Communications (NASDAQ:SBAC) from Underperform to Peer Perform.
Apellis Pharmaceuticals Q2 EPS $(2.72) Down From $(1.57) YoY
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(2.72) per share. This is a 73.25 percent decrease over losses of $(1.57) per share from the same period last year.
